Fidelity

Waymo is a self-driving technology company focused on enhancing mobility by creating safe and efficient transportation solutions. Established from advancements in Google's research since 2009, Waymo aims to improve the movement of people and goods through its innovative software and sensor technology. In 2015, the company marked a significant milestone by conducting the world's first fully autonomous trip on public roads in a vehicle devoid of traditional driving controls. Waymo continually refines its technology through extensive simulation testing, accumulating over one billion miles of virtual testing annually, while its autonomous vehicles have logged more than two million miles on public roads in four U.S. cities. By employing integrated sensors and artificial intelligence, Waymo's technology is designed to detect various obstacles such as pedestrians, cyclists, and road conditions, ensuring a safe and convenient on-demand travel experience for users.

Frore Systems is a technology company based in San Jose, California, with additional offices in Taiwan and South Korea. It specializes in the development of advanced thermal solutions for consumer devices, focusing on active cooling technologies. The company's flagship products, AirJet® Mini and AirJet® Pro, utilize piezoelectric MEMS technology to provide efficient and silent heat dissipation. These cooling chips significantly enhance device performance and offer a solid-state alternative to traditional fans, setting new benchmarks for the computing industry. Frore Systems aims to improve the overall user experience by enabling device manufacturers to implement high-performance cooling solutions in their products.

CoreWeave operates a cloud infrastructure platform that delivers computing power primarily for blockchain and artificial intelligence/machine learning projects. The company’s specialized GPU cloud system enhances workflows and allows clients to efficiently scale their operations according to the complexity of their models. This flexibility enables users to access tailored compute resources, facilitating innovation and adaptation to rapidly changing computational needs. CoreWeave's platform is designed to support a variety of initiatives, making it a valuable resource for enterprises seeking to optimize their technological capabilities.

We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The Symani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients.

AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Lightmatter specializes in developing photonic chips that leverage light for data processing and communication, significantly enhancing the speed and efficiency of artificial intelligence computations. By utilizing integrated optical technology, the company designs processors that accelerate key operations in neural networks through programmable photonic elements, which are fabricated alongside traditional transistors. This innovative approach allows for improved performance in applications such as image recognition and natural language processing while maintaining low power consumption. Lightmatter's technology primarily serves sectors including artificial intelligence, cloud computing, and telecommunications, positioning the company as a leader in light-based computing solutions.

Vention Inc. is a digital manufacturing platform based in Montreal, Canada, that simplifies the design and ordering of custom machines. Established in 2016, the company provides a cloud-based 3D Machine Builder, which allows engineers and manufacturing professionals to design, order, and assemble custom factory equipment quickly. This platform features an extensive library of modular parts, including structural, motion, and control components, facilitating the creation of automated equipment, robot cells, tooling, and conveyors. Additionally, Vention's offerings include MachineMotion, which aids both automation specialists and novices in automating their designs. By integrating artificial intelligence to enhance the design process, Vention enables users to program, simulate, and commission automated equipment within a single digital environment, making industrial automation more accessible.

Coin Metrics Inc. is a provider of blockchain and cryptocurrency data, offering comprehensive market and network analytics to various industries. The company delivers a range of services, including the CM Network Data Pro, which provides historical crypto network data aggregated daily for prominent assets, and the CM Market Data Feed, which standardizes trade, candle, and order book data across multiple exchanges. Additionally, Coin Metrics offers CM Reference Rates, which provide fixed pricing for various assets quoted in U.S. dollars. Founded in 2017 and based in Cambridge, Massachusetts, Coin Metrics aims to empower institutions and individuals to make informed decisions regarding crypto assets by providing transparent and actionable data analytics.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

Menlo Micro, Inc. is a company that specializes in the design of electronic switches, particularly its innovative Ideal Switch technology, which operates in both AC/DC and RF applications. This electromechanical switch is capable of functioning under high temperatures and stress, making it suitable for various industries including battery management, home automation, electronic vehicles, and medical instrumentation. Menlo Micro's products are also utilized in advanced applications such as high-power tunable resonators, broadband power amplifier impedance matching, electronically steerable antennas, and automated test and measurement systems. Founded in 2016 and headquartered in Irvine, California, Menlo Micro serves a diverse range of markets, including industrial Internet of Things and next-generation 5G mobile networks.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

Astera Labs is a fabless semiconductor company based in Santa Clara, California, established in 2017. The company specializes in designing and supplying semiconductors and connectivity solutions tailored for data-centric systems. Its product range includes system-aware semiconductor integrated circuits, high-speed mixed-signal connectivity products, and various system components like PCIe smart retimers, riser cards, and GPU booster cards. Astera Labs focuses on enhancing PCIe connectivity to address performance bottlenecks in compute-intensive environments, such as server connectivity, distributed machine learning, and high-end gaming graphics. The company collaborates with processor vendors, cloud service providers, and manufacturing partners to deliver critical connectivity performance and facilitate flexibility and customization in their clients' systems. Astera Labs also offers design and testing services, alongside its COSMOS software suite, which enhances observability and predictive analytics in connectivity solutions.

Veterinary Emergency Group specializes in providing emergency and urgent care for pets, operating during nights, weekends, and holidays to address acute medical issues as they arise. The organization is dedicated to delivering timely medical attention to pets and their families in critical situations. With a network of clinics staffed by trained emergency-focused personnel and equipped with advanced diagnostic tools, Veterinary Emergency Group emphasizes a customer-centered approach that ensures rapid response times year-round.

Redwood Materials, Inc. specializes in the development of innovative recycling processes aimed at creating circular supply chains for lithium-ion batteries and other electronic products. Founded by JB Straubel and based in Carson City, Nevada, the company focuses on recovering valuable materials such as lithium, nickel, copper, cobalt, and other metals from end-of-life batteries and electronics. Redwood receives approximately 10 GWh of batteries annually for recycling, which are refined and remanufactured into essential anode and cathode materials. The company is actively working to scale its production capacity to 100 GWh annually by 2025, sufficient to produce over one million electric vehicles each year. By emphasizing sustainable practices, Redwood Materials aims to reduce the environmental impact of battery production and support the growth of the electric vehicle and renewable energy storage markets.

Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.

dMed is a full-service Clinical Contract Research Organization that provides industry solutions to pharma and medical device companies. Its business covers consulting, regulatory affairs & strategy, early clinical development, clinical science & medical affairs, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, quality assurance, and information solutions. dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs around 600 professionals globally, among them 60% holds master above degree and 25% with more than 10 years working experiences.

Element Biosciences, Inc. is a life science company based in San Diego, California, that specializes in developing innovative genetic analysis tools for research and diagnostics. Established in 2017, the company focuses on creating a modular and high-performing DNA sequencing platform designed to provide high-quality data and workflow flexibility. Their proprietary technology enhances the signal-to-noise ratio and incorporates advancements in surface chemistry, instrumentation, and biochemistry. This approach significantly reduces both operational and capital costs while ensuring superior sequencing data quality, thereby making next-generation sequencing technology more accessible to medical researchers and improving their research capabilities.

SHINE Technologies specializes in the production of medical isotopes and the development of fusion technology. Its proprietary processes create essential isotopes such as molybdenum-99 and non-carrier-added lutetium-177, which are vital for diagnosing and treating serious health conditions, including heart disease and various forms of cancer. SHINE serves multiple sectors, including healthcare, aerospace, defense, and energy, providing safe and environmentally friendly solutions for industrial inspections and medical applications. The company is also focused on advancing its fusion technology to address energy challenges, including the recycling of nuclear waste. Through a phased and purpose-driven approach, SHINE aims to generate clean, abundant fusion energy, contributing to a healthier and more sustainable future.

Tenstorrent Inc. is a Canadian company that develops and manufactures application-specific integrated circuits (ASIC) focused on artificial intelligence and machine learning. Founded in 2016 and headquartered in Toronto, with an additional office in Austin, Texas, Tenstorrent specializes in providing scalable and efficient hardware solutions for various applications, ranging from battery-powered Internet of Things (IoT) devices to large cloud servers. The company’s architecture supports deep learning and enables adaptability in algorithms, catering to developers and researchers in the technology sector. By offering advanced AI hardware and software, Tenstorrent aims to enhance computational performance and facilitate the growth of machine learning technologies.

ASAPP, Inc. develops AI-native products designed to address large-scale inefficiencies in various industries. Its core offering, the ASAPP Customer Experience Performance (CXP) platform, enhances the capabilities of customer care and sales agents by providing real-time guidance on effective communication and actions during customer interactions, whether on phone calls or digital messages. The platform's machine learning models continuously learn and adapt from each customer engagement, effectively transforming every agent into a top performer without the need for extensive training or manual programming. ASAPP’s solutions are utilized by major companies in sectors such as telecom, financial services, and travel. Founded in 2014 and headquartered in New York, ASAPP also has locations in San Francisco, Mountain View, London, Buenos Aires, Ithaca, and Raleigh.

Omega Therapeutics is a development-stage biotechnology company based in Cambridge, Massachusetts, focused on developing genomic medicines aimed at curing diseases. The company utilizes its proprietary epigenomic programming platform to create a new class of programmable epigenetic medicines, referred to as Omega Epigenomic Controllers. These controllers are designed to selectively modulate genomic activity, enabling precise tuning of the human genome to treat various medical conditions. Founded in 2016 and rebranded from VL42, Inc. in 2017, Omega Therapeutics is dedicated to transforming human medicine by harnessing the innate potential of the genome for therapeutic benefits.

Emalex Biosciences is a biotechnology startup focused on developing innovative treatments for central nervous system (CNS) disorders and rare neurological conditions. Founded in 2018 by Jeff Aronin, the company is advancing its lead candidate, Ecopipam, which has been explored as a potential therapy for various CNS disorders, including pediatric Tourette Syndrome and fluency disorders. Emalex aims to address the needs of patients with rare diseases that currently have limited or no treatment options, collaborating with patient advocacy organizations and medical researchers to facilitate the development of effective biopharmaceutical therapies.

ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, focused on the development of cell and gene-based therapies for treating cancer and viral infections. Founded in 2017 by Vikas Sinha, Mitchell Finer, and David Hallal, ElevateBio operates a portfolio of companies dedicated to creating life-changing medicines. The company collaborates with leading scientists and innovators to build this portfolio and has established a centralized facility that streamlines the transition from research and development to the commercialization of these therapies. This integrated approach enhances efficiency and accelerates the availability of medical products aimed at addressing severe diseases.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Century Therapeutics is a biotechnology company focused on developing advanced cell therapies using induced pluripotent stem cells (iPSCs) to treat various cancers, including hematologic and solid tumors. Founded in 2018 and based in Philadelphia, Pennsylvania, the company utilizes a unique allogeneic iPSC-derived cell therapy platform that integrates gene editing, protein engineering, and robust manufacturing capabilities. This innovative approach allows for the generation of modified immune effector cells, such as natural killer (NK) and T cells, designed to meet significant unmet medical needs. By employing techniques like CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to enhance cell product performance and minimize rejection by the host immune system, thereby improving the efficacy of cancer treatments.

Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration, enabling physicians to regenerate heart tissue, and additional programs focused on cardiomyopathies.

Rad Power Bikes LLC, based in Seattle, Washington, is a leading manufacturer and retailer of electric bicycles in North America. Founded in 2015, the company specializes in designing feature-rich e-bikes suitable for both on and off-road use, catering to a diverse range of consumer needs. In addition to its electric bikes, Rad Power Bikes offers a variety of accessories such as bags, fenders, racks, and safety products, as well as replacement parts like batteries and tires. The company operates on a direct-to-consumer model, selling its products primarily through online platforms, which allows it to provide affordable and accessible transportation solutions. With a rapidly expanding workforce exceeding 700 employees, Rad Power Bikes is committed to revolutionizing electric mobility and promoting energy-efficient transportation options.

Vera Therapeutics, a biotechnology company based in South San Francisco, California, specializes in developing innovative biologic therapeutics aimed at treating serious immunological diseases and genetic disorders. Founded in 2016 and renamed in March 2020, the company's research focuses on transformative treatments that can significantly improve patient outcomes. One of its key product candidates is atacicept, a fusion protein designed for self-administration via a weekly subcutaneous injection. Atacicept works by inhibiting both B lymphocyte stimulator and a proliferation-inducing ligand, which are involved in the production of autoantibodies that contribute to various autoimmune diseases. Additionally, Vera Therapeutics is exploring gene-editing technologies that hold the potential to address conditions such as sickle cell disease and cystic fibrosis.

dMed is a full-service Clinical Contract Research Organization that provides industry solutions to pharma and medical device companies. Its business covers consulting, regulatory affairs & strategy, early clinical development, clinical science & medical affairs, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, quality assurance, and information solutions. dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs around 600 professionals globally, among them 60% holds master above degree and 25% with more than 10 years working experiences.

Nuro, Inc. is a technology company established in 2016 and headquartered in Mountain View, California. The company specializes in manufacturing self-driving vehicles specifically designed for local goods transportation. Nuro's autonomous delivery service enhances local commerce by enabling merchants to efficiently deliver a wide range of products, including food and pharmaceuticals, directly to customers. Their fleet of electric, fully autonomous vehicles aims to provide quick, affordable, and safe delivery options, thereby transforming the logistics of local deliveries.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.

SHINE Technologies specializes in the production of medical isotopes and the development of fusion technology. Its proprietary processes create essential isotopes such as molybdenum-99 and non-carrier-added lutetium-177, which are vital for diagnosing and treating serious health conditions, including heart disease and various forms of cancer. SHINE serves multiple sectors, including healthcare, aerospace, defense, and energy, providing safe and environmentally friendly solutions for industrial inspections and medical applications. The company is also focused on advancing its fusion technology to address energy challenges, including the recycling of nuclear waste. Through a phased and purpose-driven approach, SHINE aims to generate clean, abundant fusion energy, contributing to a healthier and more sustainable future.

Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016, that specializes in the development of innovative therapies for cancer treatment. The company's portfolio includes ATG-010 (selinexor), targeting hematologic malignancies such as multiple myeloma, and ATG-008 (onatasertib), an mTOR kinase inhibitor aimed at treating advanced solid tumors and hematological malignancies. Antengene's pipeline features several investigational products, including ATG-016 (eltanexor), ATG-527 (verdinexor), and ATG-019, along with pre-clinical candidates like ATG-101, a bi-specific antibody, and ATG-012, a KRAS G12C inhibitor. The company is committed to addressing unmet medical needs in Asia through its focus on the discovery, development, and commercialization of first-in-class therapeutics for various types of cancer.

ApplyBoard is a technology company that facilitates the study abroad experience by connecting international students, recruitment partners, and educational institutions through its comprehensive platform. By automating and streamlining the application process, ApplyBoard enables students to easily discover, apply to, and enroll in universities across North America. The company has experienced significant growth, employing over 1,200 team members and earning recognition from Deloitte as one of Canada’s fastest-growing technology firms for five consecutive years. With its headquarters in Kitchener, Ontario, and a dedicated office in Gurugram, India, ApplyBoard operates with a global workforce spread across 30 countries, including major markets such as China, the Philippines, and the United States. This extensive network allows ApplyBoard to assist thousands of students in achieving their academic aspirations abroad.

Alignment Health is a healthcare organization focused on providing tailored care solutions for seniors, primarily through Medicare Advantage plans. By offering a consumer-centric platform, it allows seniors to choose their healthcare coverage and services annually. The company emphasizes a combination of technology and clinical coordination to enhance health outcomes, facilitating care through various channels, including phone, online, and in-person settings. Additionally, Alignment Health supports its partners and patients with risk management and customized services, ensuring a comprehensive approach to healthcare delivery.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

Revolution Medicines is a clinical-stage precision oncology company dedicated to developing innovative therapies targeting challenging cancer pathways, particularly the RAS and mTOR signaling pathways. The company utilizes a unique approach that reconfigures natural substances into optimized drug candidates, building on the pioneering work of its founder, Martin D. Burke. Revolution Medicines has established an exclusive licensing agreement with the University of Illinois to utilize and further develop this transformative synthetic technology. Among its key product candidates are RMC-4630, a SHP2 inhibitor, and various programs within its RAS(ON) portfolio, along with SOS1 and 4EBP1/mTORC1 initiatives. The company's focus on harnessing complex natural products to create refined, effective therapies positions it to address significant unmet medical needs in oncology.

Allbirds, Inc. is a San Francisco-based company founded in 2015 that specializes in manufacturing eco-friendly footwear and apparel. The company offers a variety of products, including wool runners, tree runners, and loungers for men, women, and children, as well as insoles. Allbirds focuses on using premium natural materials to create sustainable footwear designed for everyday life. The brand is committed to blending comfort, good design, and sustainability, aiming to shift the shoe industry towards a more thoughtful approach. Its products are sold through both physical retail locations and online platforms, with the majority of sales generated in the United States.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

Kaleido Biosciences is a clinical-stage healthcare company that focuses on harnessing the potential of the microbiome to treat diseases and enhance human health. The company has developed a proprietary product platform that enables the efficient discovery and development of Microbiome Metabolic Therapies (MMTs). These therapies aim to modify the metabolic output and profile of the microbiome by influencing the function and distribution of its existing microbes. Kaleido is advancing a diverse pipeline of MMT candidates targeting various diseases and conditions that address significant unmet patient needs.

Cibus is a biotechnology company focused on precision gene editing in agriculture, aiming to enhance sustainability and profitability in farming. The company has developed a proprietary gene-editing technology known as the Rapid Trait Development System, which combines crop-specific cell biology platforms with various gene editing techniques. Cibus's primary objective is to create plant traits that address specific challenges in farming, including issues related to productivity, plant agronomy, diseases, pests, weeds, nutrient use, and climate adaptability. By employing advanced breeding technologies, Cibus enables precise and stable modifications in plants and other organisms without the introduction of foreign genetic material, thereby promoting environmentally friendly agricultural practices.

Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.

Atom Tickets, LLC operates a mobile application available on Android and iOS that simplifies the process of purchasing movie tickets and concessions. Founded in 2012 and based in Santa Monica, California, the app allows users to find and buy tickets while also providing features to order food in advance. It enhances the moviegoing experience by offering information such as reviews and trailers, and enabling users to share listings with friends and coordinate group outings. Users can engage with their social networks to poll friends on movie choices, book group seating while handling separate payments, and eliminate the need for physical tickets. Atom Tickets aims to streamline the entire movie experience, keeping all planning and transactions organized in one platform.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatments. Founded in 2014 and based in South San Francisco, the company’s lead product candidate, ORIC-101, is a small molecule antagonist of the glucocorticoid receptor, which is associated with resistance to various cancer therapies in solid tumors. Its second candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, targeting a critical component of the adenosine pathway linked to resistance against chemotherapy and immunotherapy. In addition to these products, ORIC is advancing multiple precision medicines aimed at addressing other mechanisms of cancer resistance. The company’s founders, Charles Sawyers and Scott Lowe, have extensive experience in identifying novel cancer targets that have led to innovative therapies.

Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutic medicines for patients with debilitating diseases and significant unmet medical needs. The company has a diverse pipeline of product candidates, primarily targeting autoinflammatory and autoimmune conditions. Its clinical-stage candidates include Rilonacept, currently in Phase III trials for recurrent pericarditis; Mavrilimumab, a monoclonal antibody in Phase II trials for giant cell arteritis; and KPL-716, which is undergoing Phase 2a trials for prurigo nodularis and Phase 1a trials for atopic dermatitis. Additionally, Kiniksa is developing KPL-404, a preclinical monoclonal antibody aimed at modulating T-cell-dependent and B-cell-mediated immunity. The company also has a collaboration with Kite Pharma to explore the combination of Mavrilimumab and Yescarta for patients with relapsed or refractory Large B-Cell lymphoma. Founded in 2015 and based in Hamilton, Bermuda, Kiniksa Pharmaceuticals employs a disciplined approach to identify and advance product candidates with strong biological rationales.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and based in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed to treat ornithine transcarbamylase deficiency. Translate Bio aims to create innovative medicines that have the potential to significantly impact the treatment landscape for rare diseases.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

Wheels Up is a membership-based private aviation company in the United States that aims to make private flying more accessible and affordable. It provides on-demand private aviation services through an innovative platform that connects consumers with safety-vetted aircraft. Members can book flights, manage their accounts, and explore ride-share options using a mobile app. Wheels Up offers a variety of travel alternatives through a combination of programmatic and charter services, utilizing both owned and leased aircraft as part of an asset-light model. Additionally, members can participate in the Wheels Down program, enhancing their overall experience. The company is dedicated to delivering flexibility, service, and safety in private aviation.

Reddit is an online platform that allows users to submit links, create content, and participate in discussions on a wide range of topics. The company focuses on providing internet content and offers various online services across diverse categories, including gaming, sports, business, cryptocurrency, and television. By fostering a community-driven environment, Reddit enables users to engage with one another, share information, and explore their interests through a unique blend of user-generated content and discussions.

Spring is a retail company that sells a wide range of items from apparel to home and garden items. It is a shopping application for iOS devices. Spring enables its users to follow the brands they love as well as purchase new arrivals, exclusives, and one-of-a-kind products. The company originally operated as Jello Labs and announced the name change in July 2014. Spring was founded by David Tisch, Alan Tisch, and Octavian Costache in New York.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and based in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed to treat ornithine transcarbamylase deficiency. Translate Bio aims to create innovative medicines that have the potential to significantly impact the treatment landscape for rare diseases.

10x Genomics is creating revolutionary DNA sequencing technology to help researchers better identify subtle variations that are overlooked by technologies that shred biological samples into tiny fragments before sequencing the short stretches and using computers to assembling them into a genome.

Magic Leap is an augmented reality company based in the United States that specializes in developing innovative hardware and software to enhance user interaction with digital devices. Its proprietary wearable technology allows users to experience augmented reality in a visually immersive manner. By leveraging dynamic-image computing and stereoscopic 3D technology, Magic Leap creates lifelike images that blend seamlessly into the real world, enhancing the way users visualize data and access digital content. The company's approach aims to bridge the gap between digital and physical experiences, enabling a unique and engaging interaction with technology through its advanced visual output capabilities.

Allena Pharmaceuticals is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, that specializes in developing and commercializing oral enzyme therapeutics for rare and severe metabolic and kidney disorders. The company's primary focus is on conditions that involve the excessive accumulation of metabolites such as oxalate and urate, which can lead to complications like kidney stones and chronic kidney disease. Allena's lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a disorder linked to significantly high urinary oxalate levels. Additionally, the company is developing ALLN-346, a novel enzyme designed to address hyperuricemia in patients with moderate to severe chronic kidney diseases. Allena Pharmaceuticals aims to provide innovative treatments that address unmet medical needs in these patient populations.

Viridian Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for patients with diseases that lack effective therapies. The company focuses on addressing conditions such as thyroid eye disease, a debilitating orphan disease characterized by inflammation and swelling of the eye muscles. One of its key product candidates, VRDN-001, is an insulin-like growth factor-1 receptor monoclonal antibody designed to potentially treat this condition. Viridian Therapeutics aims to provide new options for patients suffering from these underserved medical needs through its advanced research and development initiatives.

Bracket Computing Inc. specializes in workload isolation software that enables enterprises to securely manage workloads in hybrid cloud environments. Founded in 2011 and based in Mountain View, California, the company provides advanced IT security measures, including crypto-enforced micro-segmentation, which ensures continuous encryption of data both at rest and in motion, utilizing customer-controlled keys. Its platform also features data and runtime integrity monitoring, along with auditability and forensics capabilities that capture critical information at the time of a security breach. By consolidating security controls, Bracket Computing aims to protect enterprises from malware, insider threats, and human errors, all while maintaining the agility and speed of self-service cloud operations.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing therapies for cancer treatment. The company's lead product, entinostat, is a class I HDAC inhibitor currently in Phase III clinical trials for advanced hormone receptor positive, HER2 negative breast cancer. Additionally, entinostat is being tested in combination with Keytruda and Tecentriq in Phase Ib/II trials for non-small cell lung cancer and metastatic breast cancer. Another significant candidate, SNDX-5613, is a selective inhibitor targeting the Menin-MLL interaction, undergoing Phase I/II trials for acute leukemias. The company is also developing SNDX-6352, a monoclonal antibody for chronic graft versus host disease, currently in Phase I/II trials. Syndax has established collaborations with major pharmaceutical companies and research organizations, enhancing its research and development capabilities. Founded in 2005, Syndax Pharmaceuticals aims to address critical needs in oncology through innovative therapeutic approaches.

Afferent Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, founded in 2009. The company focuses on developing small molecule drugs aimed at treating chronic pain and various neurogenic disorders by targeting P2X3 receptors in nerve fibers. Its lead compound, AF-219, has completed two Phase 1 clinical studies and is designed to address conditions such as osteoarthritis, back pain, visceral pain, and neuropathy, as well as respiratory and urological issues.

JUUL is an electronics company based in San Francisco that focuses on providing alternatives for adult smokers through its nicotine vaporizer products. Founded with the mission to eliminate combustible cigarettes, JUUL aims to offer a viable solution for the approximately one billion smokers worldwide. The company's offerings include a range of vapes and various free-base nicotine flavors derived from natural oils and extracts, designed to deliver a satisfying smoking experience while reducing the harmful effects associated with traditional tobacco use. JUUL has reported that hundreds of thousands of smokers have successfully transitioned to its products, with plans to support millions more in making the switch in the future.

PAX Labs, Inc. is a manufacturer of premium vaporizers and accessories designed for loose-leaf and concentrates. The company's product lineup includes the PAX 3, PAX 2, and PAX Era, along with various accessories and a mobile application that enhances user experience. PAX Labs aims to simplify cannabis consumption by providing products that emphasize quality, transparency, and predictability. The company distributes its products through a network of retailers and distributors across the United States and internationally, as well as through its online platform. Founded in 2004 and headquartered in San Francisco, California, PAX Labs has established itself as an industry leader through innovation and thoughtful product design.

Twist Bioscience Corporation is a synthetic biology company based in South San Francisco, California, established in 2013. The company specializes in the production of synthetic DNA through its innovative DNA synthesis platform, which utilizes a proprietary semiconductor-based process on silicon chips. This approach allows for the rapid and cost-effective manufacturing of high-quality synthetic DNA, enabling applications in various fields, including healthcare, agriculture, industrial chemicals, and data storage. Twist Bioscience offers a range of products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA for digital data storage. The company aims to empower customers in their quest for solutions that improve lives and sustainability, positioning itself as a key player in accelerating advancements in synthetic biology.

Blue Bottle Coffee is a coffee roaster and retailer platform that delivers coffee subscriptions to doorsteps nationwide. Blue Bottle Coffee is a passionate team of hundreds around the world, united by the simple purpose of getting great coffee to everyone who asks for it whether that be in our cafes or at home. Blue Bottle is headquartered in Oakland, California, and has retail and business operations in the Bay Area, Los Angeles, New York, and Tokyo.

Axcella is a clinical-stage biotechnology company dedicated to addressing complex diseases through the use of endogenous metabolic modulator (EMM) compositions. By integrating biological pathways with advancements in systems biology and machine learning, Axcella aims to identify protein nutrients in the human diet that possess significant pharmacological effects. The company has developed a proprietary platform that has been clinically validated across various indication areas, including muscle, neurodegenerative, and liver conditions. Axcella's innovative approach seeks to enhance health outcomes by leveraging the therapeutic potential of EMMs.

Hootsuite is a social media management platform that assists businesses in engaging with their customers across various social networks. The platform offers a comprehensive suite of tools designed to simplify marketing efforts, enhance sales, and improve customer service. Users can create, schedule, publish, and manage their content and advertising campaigns from a single, secure web-based dashboard. This functionality allows organizations to efficiently manage multiple profiles, discover and schedule effective content, and gain insights into relevant data and trends, ultimately facilitating better connections with their audience.

Manthan is a leading cloud analytics company for consumer facing businesses. We excel in the application of decision sciences, advanced math and artificial intelligence and have a restless ability to invent and bring ideas to life. Manthan’s analytics solutions are powered by AI, cloud and prescriptive capabilities. They are unique in their ability to use machine intelligence to process every decision context and respond automatically with actions and recommendations to manage every aspect of a consumer business, whether its marketing, merchandising, channel/store, demand or supply. Manthan’s inventions aim to bring a new paradigm of context-aware, automated and algorithmic business decisions and actions, executed at scale.

Kobo offers an open platform for e-reading. The platform supports many formats, including EPUB and PDF, and allows its readers to buy and read digital content from a variety of sources. Kobo offers an eBook store with nearly 4 million titles across 68 languages, varying from bestsellers, self-published works, and magazines to kids’ books. It provides e-reader apps for Apple, BlackBerry, Android, and Windows platforms. Bookmarks synchronize across devices so the readers can pick up where they left off from one device to another. Kobo offers its digital reading experience to millions of readers around the world in 190 countries through its website, bookseller, and retail partner network, represented by 17,600 locations around the world. Kobo was founded in 2009 and is based in Toronto, Ontario.

Zynga Inc. is a prominent developer and operator of social games, offering a diverse portfolio that includes popular titles such as FarmVille, Words With Friends, and Zynga Poker. Founded in 2007 and headquartered in San Francisco, California, Zynga's games are accessible on mobile platforms like iOS and Android, as well as on social networking sites such as Facebook and Snapchat. The company generates revenue primarily through mobile game downloads, in-game sales of virtual goods, and advertising services, with the majority of its income stemming from online gaming. Zynga's games have been downloaded over 6 billion times globally, reaching audiences in more than 175 countries. Additionally, Zynga has developed a next-generation platform for optimizing programmatic advertising, enhancing its capabilities in the mobile advertising space. As a wholly-owned subsidiary of Take-Two Interactive Software, Zynga continues to innovate and expand its presence in the interactive entertainment industry.

BridgeCo offers processor IC and software platforms for connecting Internet media sources, computers and consumer electronics throughout the home. BridgeCo platforms are targeted at the market for stand-alone after-market and embedded audio applications. BridgeCo platforms are the core technologies underlying digital media players (DMPs), audio/video receivers (AVRs), musical instruments and external multi-channel sound cards.

Exit41's Software as a Service (SaaS) social ordering solutions have processed over twenty million food orders for consumers on behalf of leading restaurant brands across the globe including Qdoba Mexican Grill, la Madeleine, Cara Operations, Americana Group and Lettuce Entertain You Enterprises. Exit41's web and mobile applications enable restaurants to connect with, recognize and reward their customers and build loyal, profitable relationships. Founded in 1999, Exit41 is headquartered in Andover, Massachusetts, and is backed by tier one investors including GrandBanks Capital and Dace Ventures.

Yipes is a data communications services provider. It was acquired in 2007 by Indian telecommunications service provider Reliance Communications. Yipes delivers scalable business-to-business and business-to-Internet IP networking services. Their regional IP network Yipes MAN seamlessly extends your company's LAN to other business locations or to business partner locations. Their Yipes NET Internet service brings the Web to your LAN at breakaway speeds. Yipes NET customers can also take advantage of Yipes' industry-leading security offering Yipes WALL managed firewall service, to safeguard their private information from the dangers of the public Internet. Yipes NAN replaces private line and frame relay services with the simplicity of Ethernet. Yipes WEB offers a full portfolio of Internet management services. Yipes TOUGH enables customers to extend the redundancy on their customer premise to the Yipes Network.

Terabeam is an American company that designs and manufactures free-space optical transceivers for internet access in downtown areas. Terabeam was founded in 1997 and is located in Kirkland, Washington. As of August 29, 2008, the company operates as subsidiary of Renaissance Electronics & Communications LLC.